Latest stories

  • in

    Decoding Safety and Efficacy of Generic Tofacitinib Tablets in Rheumatoid Arthritis: Indian Evidence

    Decoding Safety and Efficacy of Generic Tofacitinib Tablets in Rheumatoid Arthritis: Indian Evidence

    Rheumatoid Arthritis (RA) is one of the most debilitating chronic autoimmune affecting joints leading to inflammation, pain, persistent synovitis, and eventual joint destruction. RA primarily affects small joints and may have extra-articular involvement in organs such as the lungs, heart etc. Prima facie, this disease causes severe disability, decreased quality of life and life expectancy. […] More

  • in

    Zydus Lifesciences bags USFDA nod for Azithromycin Tablets to treat certain bacterial infections

    Zydus Lifesciences bags USFDA nod for Azithromycin Tablets to treat certain bacterial infections

    Ahmedabad: Drugmaker, Zydus Lifesciences Limited, has announced that the company has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Azithromycin Tablets USP, 500 mg (USRLD: Zithromax Tablets). Azithromycin is indicated to treat certain bacterial infections such as bronchitis, pneumonia, sexually transmitted diseases (STD), infections of the ears, […] More

  • in

    Torrent Pharma unveils generic version of Keveyis tablets in US

    Torrent Pharma unveils generic version of Keveyis tablets in US

    Basking Ridge: Torrent Pharma has begun shipping the generic version of Xeris’s Keveyis (dichlorphenamide), 50mg tablets, following final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application. Torrent is distributing the product through select specialty pharmacies beginning this month. Dichlorphenamide Tablets are indicated for the treatment of primary hyperkalemic periodic […] More

  • in

    Zydus Lifesciences bags USFDA approval for Carbidopa and Levodopa Tablets to treat Parkinson’s disease symptoms

    Ahmedabad: Zydus Lifesciences Limited today  announced that the company has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Carbidopa and Levodopa Tablets USP, 10 mg/100 mg, 25 mg/100 mg, and 25 mg/250 mg (USRLD: Sinemet Tablets, 10 mg/100 mg, 25 mg/100 mg, and 25 mg/250 mg). Carbidopa […] More

  • in

    Health Canada approves Chiesi Ferriprox MR Deferiprone ER tablets for patients with transfusional iron overload

    Delhi: Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, announced that Health Canada has approved Ferriprox MR deferiprone extended-release tablets 1 000 mg for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation […] More

  • in

    Submit revised BE study protocol: CDSCO panel tells Laurus Labs on Carglumic Acid Dispersible Tablets

    New Delhi: Rejecting drug maker Laurus Lab’s proposal for clinical trial waiver of Carglumic acid dispersible tablets 200mg, the subject committee expert (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined the firm to submit a revised bioequivalence (BE) study protocol by capturing complete details such as the objective of the study, […] More